Senior Writer, National Biotech Columnist
Adam Feuerstein is a Senior Writer and National Biotech Columnist. He specializes in medicine and healthcare, with a focus on oncology, pancreatic cancer research, pharmaceutical regulation, immunotherapy, hematology, gene therapy, and mental health care. Adam's work has been featured in The Boston Globe, RamaOnHealthcare, STAT News, and TheStreet.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Adam Feuerstein's coverage primarily revolves around the healthcare and pharmaceutical industry, with a strong emphasis on providing data-driven insights and expert commentary. He frequently references press releases and cites data to support his reporting.
To effectively reach out to Adam, consider offering access to exclusive data or research findings related to biotech, healthcare, pharmaceuticals, drug development, or FDA approval processes. Additionally, experts who can provide insightful analysis of industry trends or specific events will likely capture his attention.
As Adam's geographic focus is not specified but he covers global pharmaceutical and biotech industries extensively; therefore relevant information from any part of the world would be valuable for him.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Adam Feuerstein
The European Society of Cardiology Congress that kicks off Friday in Munich will be a consequential meeting for Alnylam Pharmaceuticals, as the outlook wavers for its two ATTR-CM drugs because of a competing drug's surprising failure in the same heart disease.
The Food and Drug Administration on Thursday approved a new medicine from Roivant and its subsidiary Priovant for the treatment of dermatomyositis, a rare autoimmune disease characterized by muscle weakness and a painful skin rash.
Mimrylo, a weekly injection, is a new kind of treatment for polycythemia vera
The French drugmaker has been the subject of frenzied rumors, but it remains unbetrothed This story first appeared in Adam's Biotech Scorecard, a subscriber-only newsletter.
Company says it was pleasantly surprised by magnitude of results
By: Adam Feuerstein
Before the end of September, UniQure is expected to report four-year results from the closely tracked clinical trial of AMT-130, its gene therapy for Huntington's disease.
By: Adam Feuerstein
The success of the company's lung disease drug in a mid-stage study is a testament to its approach
By: Adam Feuerstein, Allison DeAngelis, Elaine Chen
On this week's episode of “The Readout LOUD”: The pharma industry invested billions of dollars to develop drugs heralded as the next era in the treatment of heart disease — but why did they fail?
By: Allison DeAngelis, Adam Feuerstein
The back-to-back failures of cardiovascular drugs from Novartis and Novo Nordisk made headlines earlier this month. They could also have a chilling effect across the industry.
By: Allison DeAngelis, Adam Feuerstein
Expert says that after resurgence in cardiovascular trials, investments will be harder to come by
